SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...

Cytokinetics, Incorporated has a one year low of $40.53 and a one year high of $75.71. The stock has a market capitalization of $5.11 billion, a price-to-earnings ratio of -8.03 and a beta of 0.95.

On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in the sector. He said that looking at the ...

Get Our Latest Analysis on CYTK Cytokinetics Trading Up 2.5 % CYTK stock opened at $46.57 on Tuesday. The company has a market capitalization of $5.51 billion, a PE ratio of -8.66 and a beta of 0. ...

Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

SOUTH SAN FRANCISCO, Calif. - Cytokinetics, Incorporated (NASDAQ:CYTK), a $5.1 billion market cap biotechnology company currently trading near its 52-week low, unveiled EARTH-HCM, an interactive ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment ...

SOUTH SAN FRANCISCO, Calif. - Cytokinetics, Incorporated (NASDAQ:CYTK), a $5.1 billion market cap biotechnology company currently trading near its 52-week low, unveiled EARTH-HCM, an interactive ...